Effect of statin therapy on plasma C-type Natriuretic Peptides and Endothelin-1 in males with and without symptomatic coronary artery disease
| العنوان: | Effect of statin therapy on plasma C-type Natriuretic Peptides and Endothelin-1 in males with and without symptomatic coronary artery disease |
|---|---|
| المؤلفون: | Richard W. Troughton, Timothy C. R. Prickett, Eric A. Espiner |
| المصدر: | Scientific Reports Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020) |
| بيانات النشر: | Nature Publishing Group UK, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Adult, Male, medicine.medical_specialty, Acute coronary syndrome, medicine.drug_class, Atorvastatin, Cardiology, lcsh:Medicine, Coronary Artery Disease, 030204 cardiovascular system & hematology, Article, Coronary artery disease, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Medical research, Sex Factors, In vivo, Internal medicine, medicine, Natriuretic peptide, Humans, cardiovascular diseases, Prospective cohort study, lcsh:Science, Multidisciplinary, biology, Endothelin-1, business.industry, C-reactive protein, lcsh:R, nutritional and metabolic diseases, Natriuretic Peptide, C-Type, Middle Aged, medicine.disease, Endothelin 1, 030104 developmental biology, Endocrinology, C-Reactive Protein, Treatment Outcome, Heart Function Tests, biology.protein, lcsh:Q, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Biomarkers, medicine.drug |
| الوصف: | C-type Natriuretic Peptide (CNP) and Endothelin-1 (ET-1) have reciprocal roles in maintaining vascular homeostasis and are acutely modulated by statins in human cultured endothelial cells. Whether these actions of statins in vitro are reflected in studies in vivo is unknown. In a prospective study of 66 subjects with or without post- acute coronary syndrome (ACS), plasma concentrations of bioactive CNP and bio-inactive aminoterminal proCNP (NTproCNP), ET-1, B-type Natriuretic Peptide (BNP) and high sensitivity C Reactive Protein (hsCRP) were measured together with lipids before and at intervals of 1, 2 and 7 days after commencing atorvastatin 40 mg/day - and for a further period of 6months in those with ACS. Plasma lipids fell significantly in all subjects but plasma CNP, NTproCNP and ET-1 were unchanged by atorvastatin. In ACS, baseline hsCRP, BNP and CNP but not NTproCNP or ET-1 were significantly raised compared to values in age-matched controls. The ratio of NTproCNP to CNP was significantly lower in ACS throughout the study and was unaffected by statin therapy. We conclude that conventional doses of atorvastatin do not affect plasma CNP products or ET-1. Elevated CNP after cardiac injury likely results from regulated changes in clearance, not enhanced production. |
| اللغة: | English |
| تدمد: | 2045-2322 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::380f8c9aa39d521f5cdfd5929b8fc848Test http://europepmc.org/articles/PMC7220949Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....380f8c9aa39d521f5cdfd5929b8fc848 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20452322 |
|---|